This legislation aims to enhance the reliability of the supply chain for essential medications and their components, particularly during public health emergencies. It seeks to ensure that there are sufficient reserves of critical drugs and active pharmaceutical ingredients (APIs) to prevent shortages. Key provisions include the establishment of a program allowing the Secretary of Health and Human Services to enter into agreements with eligible manufacturers to maintain a six-month reserve of critical drugs and APIs.